A recent literature review on testosterone therapy’s impact on cardiovascular health found that while the TRAVERSE trial showed no increased risk for major cardiovascular events, other studies have yielded different results. The review, which included 11 prospective cohort studies, found that men with very low testosterone, high luteinizing hormone, or very low estradiol concentrations had higher mortality rates. Additionally, high sex hormone-binding globulin levels were linked to increased mortality. The study also highlighted a U-shaped association between dihydrotestosterone levels and mortality. The rigorous methodology used in the review adds value to the findings, suggesting that testosterone therapy may benefit patients with very low testosterone levels. Further research is needed to explore these relationships.
Source link
Testosterone/CVD Risk Debate Revived by New Meta-Analysis
